In8bio To Present New Data From Phase 1 Trial Of INB-100 At 2023 ASH Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
In8bio is set to present new data from its Phase 1 trial of INB-100 at the 2023 ASH Annual Meeting. The data shows promising efficacy of INB-100 in patients with hematologic malignancies, with no dose-limiting toxicities and evidence of robust gamma-delta T cell expansion.
November 02, 2023 | 1:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
In8bio's new data from its Phase 1 trial of INB-100 shows promising results, which could potentially boost investor confidence in the company.
The promising results from the Phase 1 trial of INB-100 could potentially increase investor confidence in In8bio. The absence of dose-limiting toxicities and the evidence of robust T cell expansion are positive indicators of the drug's potential success.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100